Association between early weight variation and treatment outcomes among extensively drug-resistant tuberculosis patients in Pakistan: a multicenter retrospective cohort study

Tuberculosis (TB) is commonly associated with significant weight loss, and weight gain during treatment is often considered an indicator of treatment response. However, evidence regarding the association between weight change and treatment outcomes among patients with extensively drug-resistant TB (XDR-TB) remains limited. This study aimed to evaluate the relationship between weight change during treatment and treatment outcomes among XDR-TB patients in Pakistan. A multicenter retrospective cohort study was conducted using data from XDR-TB patients treated at 27 Programmatic Management of Drug-Resistant TB units across Pakistan between May 2010 and June 2019. Patient data were extracted from the Electronic Nominal Recording and Reporting System of the National Tuberculosis Control Program. Weight change was assessed at 2, 4, and 6 months of treatment and categorized as no weight gain, weight gain <4 kg, and ≥4 kg. Logistic regression analysis was performed to determine the association between weight gain and favorable treatment outcomes. A total of 255 XDR-TB patients were included in the final analysis. Among them, 54.9% were male, and the majority (52.2%) belonged to the 21-40 year age group. Overall, favorable treatment outcomes were observed in 54.9% of patients. In multivariate analysis, weight gain at the fourth month of treatment showed a statistically significant negative association with favorable treatment outcomes for both weight gain <4 kg (OR 0.343, p=0.039) and ≥4 kg (OR 0.370, p=0.020). No statistically significant association was observed between weight gain at two or six months and treatment outcomes. These findings suggest that weight gain during treatment may not be a reliable predictor of favorable treatment outcomes among XDR-TB patients, and additional clinical and microbiological indicators should be considered when monitoring treatment response.

Abubakar M, Ahmad N, Ghafoor A, et al. Treatment outcomes of extensively drug-resistant tuberculosis in pakistan: a countrywide retrospective record review. Front Pharmacol 2021;12:640555. DOI: https://doi.org/10.3389/fphar.2021.640555

World Health Organization. Global tuberculosis report 2025. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025.

Yirenkyi SO. The burden of extensively drug resistant and pre-extensively drug resistant tuberculosis among multidrug-resistant mycobacterium tuberculosis patients in Ghana. University of Ghana; 2022.

Abubakar M, Ahmad N, Atif M, et al. Prognostic accuracy of time to sputum culture conversion in predicting cure in extensively drug-resistant tuberculosis patients: a multicentre retrospective observational study. BMC Infect Dis 2022;22:204. DOI: https://doi.org/10.1186/s12879-022-07202-y

Utpat KV, Rajpurohit R, Desai U. Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era. Lung India 2023;40:19-23. DOI: https://doi.org/10.4103/lungindia.lungindia_182_22

Balinda IG, Sugrue DD, Ivers LC. More than malnutrition: a review of the relationship between food insecurity and tuberculosis. Open Forum Infect Dis 2019;6:ofz102. DOI: https://doi.org/10.1093/ofid/ofz102

Bernabe-Ortiz A, Carcamo CP, Sanchez JF, Rios J. Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS One. 2011;6(4):e18474. DOI: https://doi.org/10.1371/journal.pone.0018474

Chakhaia T, Blumberg HM, Kempker RR, et al. Lack of weight gain and increased mortality during and after treatment among adults with drug-resistant tuberculosis: a retrospective cohort study in Georgia, 2009–2020. ERJ Open Research 2025;11. DOI: https://doi.org/10.1101/2024.08.05.24311499

Warmelink I, ten Hacken NH, van der Werf TS, van Altena R. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 2011;105:400-8. DOI: https://doi.org/10.1017/S0007114510003636

Wilson JW, Tsukayama DT. Extensively drug-resistant tuberculosis: principles of resistance, diagnosis, and management. Mayo Clin Proc 2016;91:482-95. DOI: https://doi.org/10.1016/j.mayocp.2016.01.014

Wagnew F, Alene KA, Kelly M, Gray D. Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia. Sci Rep 2024;14:508. DOI: https://doi.org/10.1038/s41598-023-51026-y

Akhtar AM, Kanwal S, Majeed S, Majeed W. Weight variation increases the risk of death during the intensive phase of treatment among MDR-TB patients: a retrospective study. Pak J Med Sci 2023;39:1080-5. DOI: https://doi.org/10.12669/pjms.39.4.7025

Yen YF, Tung FI, Ho BL, Lai YJ. Underweight increases the risk of early death in tuberculosis patients. Br J Nutr 2017;118:1052-60. DOI: https://doi.org/10.1017/S0007114517003166

Castello FA, Sosa EJ, Campos J, et al. Genomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006–2015). BMC Infect Dis 2025;25:1602. DOI: https://doi.org/10.1186/s12879-025-11913-3

World Health Organization. Global tuberculosis report 2023. Available from: https://www.who.int/publications/i/item/9789240083851.

Naz F, Ahmad N, Wahid A, et al. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis. BMC Infect Dis 2021;21:1209. DOI: https://doi.org/10.1186/s12879-021-06935-6

Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392:821-34. DOI: https://doi.org/10.1016/S0140-6736(18)31644-1

Gler MT, Guilatco R, Caoili JC, et al. Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg 2013;89:943-9. DOI: https://doi.org/10.4269/ajtmh.13-0011

Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Bernabe-Ortiz A. Weight variation over time and its relevance among multidrug-resistant tuberculosis patients. Int J Infect Dis 2014;23:20-4. DOI: https://doi.org/10.1016/j.ijid.2014.01.001

Marçôa R, Ribeiro A, Zão I, Duarte R. Tuberculosis and gender–factors influencing the risk of tuberculosis among men and women by age group. Pulmonology 2018;24:199-202. DOI: https://doi.org/10.1016/j.pulmoe.2018.03.004

Pradipta IS, Forsman LD, Bruchfeld J, et al. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect 2018;77:469-78. DOI: https://doi.org/10.1016/j.jinf.2018.10.004

Frank M, Adamashvili N, Lomtadze N, et al. Long-term follow-up reveals high posttreatment mortality rate among patients with extensively drug-resistant tuberculosis in the country of Georgia. Open Forum Infect Dis 2019;6:ofz152. DOI: https://doi.org/10.1093/ofid/ofz152

Kwon YongSoo KY, Kim YeeHyung KY, Suh GeeYoung SG, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. DOI: https://doi.org/10.1086/590005

Tabarsi P, Chitsaz E, Baghaei P, et al. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microb Drug Resist 2010;16:81-6. DOI: https://doi.org/10.1089/mdr.2009.0073

Saifullah A, Mallhi TH, Khan YH, et al. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: a retrospective cohort study. PeerJ. 2021;9:e10826. DOI: https://doi.org/10.7717/peerj.10826

Belkina T. Non-prescribed antibiotic use in some developing countries and its association with drug resistance. 2017.

Lee T, Lee SJ, Jeon D, et al. Additional drug resistance in patients with multidrug-resistant tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci 2021;36:e174. DOI: https://doi.org/10.3346/jkms.2021.36.e174

Alderwick LJ, Harrison J, Lloyd GS, Birch HL. The mycobacterial cell wall—peptidoglycan and arabinogalactan. Cold Spring Harbor Perspect Med 2015;5:a021113. DOI: https://doi.org/10.1101/cshperspect.a021113

Dookie N, Ngema SL, Perumal R, et al. The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives. Clin Microbiol Rev 2022;35:e00180-19. DOI: https://doi.org/10.1128/cmr.00180-19

Omoteso OA, Fadaka AO, Walker RB, Khamanga SM. Innovative strategies for combating multidrug-resistant tuberculosis: advances in drug delivery systems and treatment. Microorganisms 2025;13:722. DOI: https://doi.org/10.3390/microorganisms13040722

Shi D, Zhou Q, Xu S,et al. Pyrazinamide resistance and pncA mutation profiles in multidrug resistant Mycobacterium tuberculosis. Infect Drug Resist 2022:4985-94. DOI: https://doi.org/10.2147/IDR.S368444

Phan MN, Guy ES, Nickson RN, Kao CC. Predictors and patterns of weight gain during treatment for tuberculosis in the United States of America. Int J Infect Dis 2016;53:1-5. DOI: https://doi.org/10.1016/j.ijid.2016.09.006

Barnwal RK, Gawande AV, Narlawar UW, Zurmure SA. Impact of anti-tubercular treatment on weight and symptoms of category I tuberculosis patients in an urban city of central India. Int J Community Med Public Health 2020;7:491-4. DOI: https://doi.org/10.18203/2394-6040.ijcmph20200051